evidence: The mean change in HbA1c (from baseline to end‐point, week 24) was −1.2 ± 0.3% in the combination group and −0.3 ± 0.5% in switching group, and the difference was significant (P < 0.001
intervention: Combining nateglinide + vildagliptin
comparator: Switching from nateglinide to vildagliptin
outcome: Achieving target HbA1c